M6-C Post Approval Study (PAS)

M6-C Artificial Cervical Disc IDE Post Approval Study

The M6-C Post Approval Study is a long term follow-up study of subjects previously enrolled and treated in the M6-C Artificial Cervical Disc IDE Study.

Study Overview

• Status: Enrolling by invitation
• Conditions: Long Term Follow-up
• Intervention / Treatment: Other: standard radiographic imaging

Detailed Description

A prospective, concurrently controlled, multi-center pivotal study to evaluate the safety and effectiveness of the M6-C™ Artificial Cervical Disc compared to anterior cervical discectomy and fusion (ACDF) was performed in the United States under IDE #G050254. To fulfill the concurrent control design of the study, there were clinical sites that evaluated the safety and effectiveness of the M6-C™ Artificial Cervical Disc and there were other clinical sites that evaluated ACDF. Subjects in the study were treated between May 2014 and June 2016 and remain in follow-up. The M6-C™ Artificial Cervical Disc received FDA approval to market on February 6, 2019. As a condition of approval, the FDA requested that the sponsor perform a post market approval study (PAS). The subjects enrolled and remaining in the M6-C IDE pivotal study are the prospective patient population for the PAS.

• Study Type: Observational
• Enrollment (Anticipated): 208

Contacts and Locations

Study Locations

• United States
  • California
    • Sunnyvale, California, United States, 94085
      • Spinal Kinetics, LLC

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 21 years to 68 years (Adult, Older Adult)
• Accepts Healthy Volunteers: No
• Genders Eligible for Study: All

• Sampling Method: Probability Sample

Study Population

Subjects eligible for study enrollment will include subjects implanted in the M6-C™ IDE pivotal study

Description

Inclusion Criteria:

• Since the subjects have already been screened as part of the IDE's pivotal study, and only subjects that participated in that study make up the subject cohort for this long-term follow-up study, there are no additional inclusion criteria

Exclusion Criteria:

• Subjects who were withdrawn or withdrew consent to participate in the investigation
• Subjects who do not consent to participate in long-term follow-up or provide personal contact information to the sponsor (solely for the purposes of tracking subjects to help ensure follow-up compliance)
• Patients with terminal failures (SSI or device- or procedure-related SAE) by Month 24 and all known patient deaths in the M6-C IDE study are excluded for enrollment into the PAS

Study Plan

How is the study designed?

Design Details

• Observational Models: Cohort
• Time Perspectives: Prospective

Number of groups / cohorts

2

Cohorts and Interventions

Group / Cohort	Intervention / Treatment
M6-C; Subjects treated with an M6-C device	Other: standard radiographic imaging; standard radiographic imaging
ACDF; Subjects treated with Anterior Cervical Discectomy and Fusion (ACDF)	Other: standard radiographic imaging; standard radiographic imaging

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Overall subject success	A study subject will be considered an overall success if he/she meets the following criteria: No serious adverse event(s) classified as device or device procedure related (as determined by the CEC), and; No subsequent surgical procedure at the index level (including revision, removal, reoperation, or supplemental fixation), and; Maintenance or improvement in neurological function, and; Improvement on the NDI of at least 15 points.	10 year follow-up

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Neck Disability Index (NDI)	The NDI is a patient reported outcome questionnaire for the measurement of pain and function related to cervical spine problems. A total NDI score is determined by adding the scores of the individual questions and dividing that total by the maximum possible score (i.e., 50 if all questions are answered) to yield a percentage. Therefore, the NDI score ranges from 0% to 100%. A lower score represents less pain and dysfunction.	annually to 10 years
Neck and arm pain	A visual analogue scale is a patient reported outcome measure utilized to determine neck and arm pain on a zero to ten scale with zero being the least amount of pain and 10 the most possible pain.	annually to 10 years
SF-36 Health Survey	The SF-36 is a patient reported outcome questionnaire to measure health-related Quality of Life. An increase in score from baseline represents an improvement in health.	annually to 10 years
Patient Satisfaction	The following 5 point Likert Scale will be used to further assess subject satisfaction: How satisfied are you with the results of your surgery? Very Satisfied; Satisfied; Neutral; Unsatisfied; Very Unsatisfied; All things considered, would you have the surgery again? Very likely; likely; not sure; Unlikely; Very Unlikely; Would you recommend the surgery to a friend or family member? Very likely; likely; not sure; Unlikely; Very Unlikely	annually to 10 years
Odom's Criteria	At the 5, 7 and 10 year follow-up visits, the Investigator will rate the clinical disposition of each study subject according to Odom's Criteria[18] as follows: Excellent: No symptoms related to cervical disease. Able to perform daily activities without limitations. Good: Moderate symptoms related to cervical disease. Able to perform daily activities without significant limitations. Satisfactory: Slight improvement is symptoms related to cervical disease. Significant limitations in daily activities. Poor: No improvement in, or aggravation of, symptoms related to cervical disease. Not able to perform daily activities.	annually to 10 years

Collaborators and Investigators

• Sponsor: Spinal Kinetics

Study record dates

Study Major Dates

• Study Start (Anticipated): November 30, 2019
• Primary Completion (Anticipated): June 30, 2026
• Study Completion (Anticipated): June 30, 2026

Study Registration Dates

• First Submitted: October 8, 2019
• First Submitted That Met QC Criteria: October 9, 2019
• First Posted (Actual): October 10, 2019

Study Record Updates

• Last Update Posted (Actual): October 14, 2019
• Last Update Submitted That Met QC Criteria: October 9, 2019
• Last Verified: October 1, 2019

More Information

Terms related to this study

• Other Study ID Numbers: CA-C004

Plan for Individual participant data (IPD)

• Plan to Share Individual Participant Data (IPD)?: No

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: No
• Studies a U.S. FDA-regulated device product: Yes
• product manufactured in and exported from the U.S.: Yes